PCT patent filed for NIPDx fetal cell based NIPT

Great new – The IP underpinning NIPDx Pty Ltd has progressed t the PCT phase with the support of UniSA Ventures.

NIPDx is a spin-off company aimed at developing a next generation NIPT technology based on circulating fetal cells isolated from maternal blood. The need for better and more reliable NIPT has been recently illustrated in this article by the BBC UK:

‘I nearly aborted my baby because of an unreliable test’ – read the full article here.

Comments are closed.